
    
      TOP is an epidemiological observational study of participants receiving natalizumab, with
      each participant to be followed for up to 15 years. This study is designed to address the
      long-term safety profile and the long-term impact on disease activity and progression of
      Tysabri with marketed use, and the impact of treatment on disability in particular by
      comparing the results with prospectively determined controls from established databases.
    
  